Daniel Mason Dow, M.D. Radiology - Diagnostic Radiology Medicare: Not Enrolled in Medicare Practice Location: 909 Rockwall Pkwy, Rockwall, TX 75032 Phone: 469-698-0045 Fax: 469-698-0483 |
Dr. Ram Priya Chaturvedi, M.D. Radiology - Diagnostic Radiology Medicare: Medicare Enrolled Practice Location: 1872 Huron Drive, Rockwall, TX 75087 Phone: 214-628-3459 |
Dr. Andrea Lynn Lundell, M.D, Radiology - Body Imaging Medicare: Medicare Enrolled Practice Location: 105 Liberty Ln, Rockwall, TX 75032 Phone: 972-722-3766 |
Dr. Andres U Katz, MD Radiology - Diagnostic Radiology Medicare: Medicare Enrolled Practice Location: 103 N 1st St, Rockwall, TX 75087 Phone: 972-771-5366 Fax: 972-771-0424 |
Dr. Thomas Saadeh, M.D. Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 909 Rockwall Pkwy, Rockwall, TX 75032 Phone: 460-698-0045 Fax: 469-698-0483 |
News Archive
Takeda Pharmaceuticals North America today announced that the company has submitted a New Drug Application (NDA) for a new oral medication that combines pioglitazone HCl and glimepiride, a sulfonylurea, to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes.
According to information in the article, more than 40,000 new cases of head and neck cancer are diagnosed annually in the United States, with 12,000 deaths each year. Patients with head and neck cancer often experience problems with eating and communicating, have pain, and have poor emotional well being and general functional status.
With this week's vote to repeal President Obama's health care reform, House Republicans struck a blow for freedom. They struck a blow for the freedom of hospitals to avoid financial penalties, no matter how many Medicare patients develop infections under their care. They struck a blow for the freedom of hospitals to avoid consequences, no matter how many Medicare patients are reĀadmitted soon after treatment.
Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood's Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).
A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year.
› Verified 1 days ago